Proto Labs vs Innovate
PRLB and VATE side by side, both in fabricated metal products, except machinery and transportation equipment. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PRLB and VATE compare
Proto Labs is the larger company, worth 23 times as much as Innovate ($1.6B against $71.9M).
Innovate grew revenue faster over the last twelve months (52.4% versus 11.8% for Proto Labs).
Proto Labs keeps more of each dollar of sales as profit, with a net margin of 6.0% compared with −1.5% at Innovate.
Proto Labs scores higher on the StockData Score (14 against 8 for Innovate), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PRLB | VATE |
|---|---|---|
| Size and price | ||
| Market cap | $1.6B | $71.9M |
| Share price | $69.11 | $5.27 |
| Change, 1 year | 41.0% | −4.2% |
| Change, 5 years | 30.6% | −87.7% |
| Beta (5Y) | 1.29 | 1.85 |
| Employees | 2,280 | 3,587 |
| StockData Score | ||
| Total score | 14 (better) | 8 |
| Valuation score | 1 | 4 (better) |
| Growth score | 4 (better) | 1 |
| Performance score | 3 (better) | 2 |
| Health score | 6 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 48.3× | – |
| P/S | 2.8× | 0.0× (better) |
| P/B | 2.4× | – |
| EV/EBITDA | 20.0× | 7.0× (better) |
| P/FCF | 33.9× | 0.5× (better) |
| FCF yield | 2.9% | 196% (better) |
| Fair value | $46.68 | $46.04 |
| Margin of safety | −48.1% | 88.6% (better) |
| Growth | ||
| Revenue growth (TTM) | 11.8% | 52.4% (better) |
| Revenue growth, 5Y average | 4.2% | 11.7% (better) |
| Net income growth (TTM) | 136% | – |
| EPS growth (TTM) | 134% | – |
| EPS growth, 5Y average | −14.2% | – |
| Profitability | ||
| Gross margin | 45.2% (better) | 15.9% |
| Operating margin | 7.3% (better) | 4.3% |
| Net margin | 6.0% (better) | −1.5% |
| FCF margin | 8.4% | 9.3% (better) |
| Return on equity | 5.1% | – |
| Return on invested capital | 5.6% | 15.3% (better) |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Net debt / EBITDA | – | 6.02 |
| Interest coverage | – | 0.7× |
| Current ratio | 3.65 (better) | 0.44 |
| Altman Z-score | 10.97 (better) | 0.22 |
| Piotroski F-score | 7 (better) | 4 |
| Dividends and buybacks | ||
| Buyback yield | 0.99% | – |
| Shareholder yield | 0.99% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 94.2% | 23.0% |
| Held by insiders | 1.9% | 59.9% |
| Insider net buying, 12 months | −$3.1M | – |
| Short interest, % of float | 2.6% | 9.9% |
Go deeper
- PRLB stock overview
- PRLB income statement
- PRLB valuation and score
- VATE stock overview
- VATE income statement
- VATE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.